IL202828A0 - 6-(pyrrolopyridinyl)pyrimidin - 2 - ylamine derivatives and the use thereof for the treatment of cancer and aids - Google Patents

6-(pyrrolopyridinyl)pyrimidin - 2 - ylamine derivatives and the use thereof for the treatment of cancer and aids

Info

Publication number
IL202828A0
IL202828A0 IL202828A IL20282809A IL202828A0 IL 202828 A0 IL202828 A0 IL 202828A0 IL 202828 A IL202828 A IL 202828A IL 20282809 A IL20282809 A IL 20282809A IL 202828 A0 IL202828 A0 IL 202828A0
Authority
IL
Israel
Prior art keywords
pyrrolopyridinyl
pyrimidin
aids
cancer
treatment
Prior art date
Application number
IL202828A
Other languages
English (en)
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of IL202828A0 publication Critical patent/IL202828A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL202828A 2007-06-21 2009-12-17 6-(pyrrolopyridinyl)pyrimidin - 2 - ylamine derivatives and the use thereof for the treatment of cancer and aids IL202828A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007028515A DE102007028515A1 (de) 2007-06-21 2007-06-21 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
PCT/EP2008/004151 WO2008155000A1 (de) 2007-06-21 2008-05-23 6-(pyrrolopyridinyl)- pyrimidin-2-yl-amin-derivate und ihre verwendung zur behandlung von krebs und aids

Publications (1)

Publication Number Publication Date
IL202828A0 true IL202828A0 (en) 2010-06-30

Family

ID=39916277

Family Applications (1)

Application Number Title Priority Date Filing Date
IL202828A IL202828A0 (en) 2007-06-21 2009-12-17 6-(pyrrolopyridinyl)pyrimidin - 2 - ylamine derivatives and the use thereof for the treatment of cancer and aids

Country Status (16)

Country Link
US (1) US8546390B2 (enExample)
EP (1) EP2155745B1 (enExample)
JP (1) JP5411849B2 (enExample)
KR (1) KR20100040862A (enExample)
CN (1) CN101679425B (enExample)
AR (1) AR067081A1 (enExample)
AU (1) AU2008266584B2 (enExample)
BR (1) BRPI0812944A2 (enExample)
CA (1) CA2691223C (enExample)
DE (1) DE102007028515A1 (enExample)
EA (1) EA016160B1 (enExample)
ES (1) ES2533873T3 (enExample)
IL (1) IL202828A0 (enExample)
MX (1) MX2009013341A (enExample)
WO (1) WO2008155000A1 (enExample)
ZA (1) ZA201000432B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2078020A4 (en) * 2007-04-10 2011-10-19 Sgx Pharmaceuticals Inc HETEROCYCLIC MODULATORS WITH FUSED CYCLES FOR KINASES
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE102009019962A1 (de) * 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
DE102009060174A1 (de) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE102009060175A1 (de) 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
DE102010050558A1 (de) * 2010-11-05 2012-05-10 Merck Patent Gmbh 1H-Pyrrolo[2,3-b]pyridinderivate
DE102010053347A1 (de) * 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
DE102011009961A1 (de) 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
CN105732639A (zh) 2012-06-29 2016-07-06 辉瑞大药厂 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
TWI498325B (zh) * 2013-01-18 2015-09-01 Hoffmann La Roche ３－取代吡唑及其用途
JP6325078B2 (ja) * 2013-03-15 2018-05-16 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． ヘテロ環式化合物およびその使用
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
EP3083618B1 (en) 2013-12-17 2018-02-21 Pfizer Inc Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
WO2017161004A1 (en) 2016-03-15 2017-09-21 University Of South Florida PKCδ INHIBITOR FORMULATIONS AND USES THEREOF CROSS-REFERENCE TO RELATED APPLICATIONS
CA3017388C (en) 2016-04-01 2024-03-12 Zeno Royalties & Milestones, LLC Estrogen receptor modulators
EP3694855A1 (en) 2017-10-13 2020-08-19 Plexxikon Inc. Solid forms of a compound for modulating kinases
CN113710668B (zh) * 2019-04-09 2025-01-07 Opna生物公司 用于ep300或cbp调节及其适应症的缩合吖嗪
US11278532B2 (en) 2019-08-06 2022-03-22 Recurium Ip Holdings, Llc Estrogen receptor modulators for treating mutants
CN118772140A (zh) * 2023-04-07 2024-10-15 四川大学 一类化合物及其在治疗hDHODH介导的疾病中的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
US6265434B1 (en) 1999-04-06 2001-07-24 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
NZ584499A (en) * 2004-03-30 2011-08-26 Vertex Pharma Azaindoles Useful as Inhibitors of Jak and Other Protein Kinases
WO2005123672A2 (en) * 2004-06-14 2005-12-29 Takeda San Diego, Inc. Kinase inhibitors
US7361763B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US20090233955A1 (en) * 2004-12-08 2009-09-17 Frazee James S 1H-Pyrrolo[2,3-B]Pyridnes
AU2006247322A1 (en) * 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
DE102006012617A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate

Also Published As

Publication number Publication date
JP5411849B2 (ja) 2014-02-12
KR20100040862A (ko) 2010-04-21
US8546390B2 (en) 2013-10-01
ZA201000432B (en) 2010-10-27
BRPI0812944A2 (pt) 2014-12-16
EA201000004A1 (ru) 2010-06-30
EP2155745B1 (de) 2015-01-28
JP2010530376A (ja) 2010-09-09
WO2008155000A1 (de) 2008-12-24
AU2008266584B2 (en) 2013-04-04
CA2691223C (en) 2015-12-01
CN101679425B (zh) 2013-11-06
AU2008266584A1 (en) 2008-12-24
CA2691223A1 (en) 2008-12-24
ES2533873T3 (es) 2015-04-15
EP2155745A1 (de) 2010-02-24
DE102007028515A1 (de) 2008-12-24
US20110082140A1 (en) 2011-04-07
MX2009013341A (es) 2010-01-18
AR067081A1 (es) 2009-09-30
CN101679425A (zh) 2010-03-24
EA016160B1 (ru) 2012-02-28

Similar Documents

Publication Publication Date Title
IL202828A0 (en) 6-(pyrrolopyridinyl)pyrimidin - 2 - ylamine derivatives and the use thereof for the treatment of cancer and aids
IL195731A0 (en) Pyrimidine derivatives useful in the treatment of cancer
ZA201000075B (en) Purin derivatives for use in the treatment of fab-related diseases
AP2960A (en) Substituted pyrimidines for the treatment of diseases such as cancer
ZA201202384B (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
IL210802A0 (en) Purin derivatives for use in the treatment of fab-related diseases
ZA201109384B (en) Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
IL213070A0 (en) Methods for the treatment of infections and tumors
IL192763A (en) History of pyrimidine, preparations containing them and used in the preparation of cancer drugs
ZA201000087B (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
HUE037109T2 (hu) Endoxifén rák kezelésében történõ alkalmazásra
IL201449A0 (en) Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
ZA201003425B (en) 5-cyano-thienopyridines for the treatment of tumors
IL200966A0 (en) Tetrahydroquinoline derivatives and the use thereof for the treatment of cancer
IL206189A (en) Compounds for use in cancer treatment
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
IL226363A0 (en) Compounds and methods for treating cancer
GB0517387D0 (en) Combinations for the treatment of cancer
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
IL205339A0 (en) Compounds and methods for the treatment of cancer
ZA200810524B (en) Pyrimidine derivatives useful in the treatment of cancer
GB0700281D0 (en) Methods and Means for the Treatment of Cancer
GB0517386D0 (en) Combinations for the treatment of cancer
HK1170238A (en) Indolyl-substituted pyrazino-quinolines and their use for the treatment of cancer
HK1166787A (en) Jak2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer